CITRYLL003 Enrolling

Adult Hidradenitis Suppurativa Study (5 Months)


Treatment: Injection Age: 18 Years and above




Who Can Participate?

Adults aged 18 and older with hidradenitis suppurativa may participate.

Inclusion Criteria

  • have had hidradenitis suppurativa for at least 6 months
  • 5 or more abscesses and inflammatory nodules
  • Lesions in 2 or more distinct anatomic areas
  • Inadequate response to oral antibiotics


Participant Information
 

  • Participate and receive study treatment at no cost
  • Regular visits with study doctors who specialise in treating hidradenitis suppurativa (12 visits)
  • Will receive either an investigative injection treatment (study drug) or a placebo
  • Reimbursement for study-related expenses may be provided

    How Long Will The Study Last?
  • 22 weeks

Participating Locations

Participating Experts

No Doctors Found

You May Also Be Interested In

Similar Trials

No Similar Trials Found

The following information is from ClinicalTrials.gov

Last Update Posted: November 06, 2025

Official Title

A Phase 2a Double Blind, Randomized, Parallel Arm, Placebo-controlled Trial to Investigate the Effects of Two Dose Levels of CIT-013 on Disease Activity in Patients With Hidradenitis Suppurativa

ClinicalTrials.gov ID

NCT06993233

Sponsor

Citryll BV

Study Description

  • Brief Summary:

    The goal of this clinical trial is to learn if CIT-013 works to treat Hidradenitis Suppurativa in adults. It will also learn about the safety of CIT-013. The main questions it aims to answer are: Does CIT-013 lower the disease activity of HS patients? What medical problems do participants have when receiving CIT-013? Researchers will compare CIT-013 to a placebo (a look-alike substance that contains no drug) to see if CIT-013 works to treat the symptoms of HS. Participants will: Take receive 50 or 100 mg CIT-013 or placebo every other week for 12 weeks Visit the clinic once every 2 weeks for checkups and tests Keep monitor their symptoms during this period

  • Condition or Disease:

    Hidradenitis Suppurativa (HS)

  • Intervention/Treatment:

    Drug: CIT-013 high dose Drug: CIT-013 medium dose Drug: Placebo
  • Phase:

    PHASE2

  • Ages Eligible for Study:

    18 Years and older (ADULT,OLDER_ADULT)

  • Sexes Eligible for Study:

    ALL


Terms and Conditions – ClinicalTrials.gov
Purpose of ClinicalTrials.gov Database. The U.S. National Institutes of Health, Department of Health and Human Services, through its National Library of Medicine, has developed ClinicalTrials.gov to provide patients, family members, and members of the public current information about clinical research studies.



about-icon

Learn More About

Hidradenitis Suppurativa

Learn More
2025 all rights reserved Probity Medical Research Inc
find a trial
General Registration

Can’t find a trial? Not sure which trial to choose? Complete a general registration and we’ll contact you with suitable trials.

Register
filter trials
Skip to content